Showing results (261-270 of 470) with videos related to

Sort By:
Pageof 47
Molecular Cancer Therapeutics|November 2, 2021
Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal CancersMichael Cerniglia, Joanne Xiu, Axel Grothey, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
The Lancet. Oncology|December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trialsThierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Breast Cancer Research and Treatment|August 31, 2022
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution studyGrace M Choong, Savannah Liddell, Roberto A Leon Ferre, et al.
Plos One|May 24, 2014
The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeletonAnne Gingery, Malayannan Subramaniam, Kevin S Pitel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2023
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast CancerGary N Schwartz, Peter A Kaufman, Karthik V Giridhar, et al.
AJR. American Journal of Roentgenology|June 6, 2019
Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant ChemotherapyKatie N Hunt, Amy Lynn Conners, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Mothaffar F Rimawi, Ingrid A Mayer, Andres Forero, et al.
Clinical Pharmacology and Therapeutics|May 28, 2021
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast CancerJunmei Cairns, Krishna R Kalari, James N Ingle, et al.
Pageof 47